Omeros Co. (NASDAQ:OMER) CAO Michael A. Jacobsen sold 8,100 shares of Omeros stock in a transaction dated Monday, February 22nd. The stock was sold at an average price of $23.28, for a total value of $188,568.00. Following the transaction, the chief accounting officer now owns 24,000 shares in the company, valued at $558,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of NASDAQ:OMER traded down $0.52 during midday trading on Tuesday, reaching $22.15. The company had a trading volume of 665,375 shares, compared to its average volume of 829,944. The business’s 50 day moving average price is $19.52 and its 200 day moving average price is $14.03. The stock has a market cap of $1.37 billion, a PE ratio of -9.31 and a beta of 1.65. Omeros Co. has a 1-year low of $8.50 and a 1-year high of $25.46.
Several research firms have issued reports on OMER. Zacks Investment Research downgraded Omeros from a “buy” rating to a “hold” rating in a research note on Friday, November 20th. HC Wainwright lifted their price target on Omeros from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, January 20th. UBS Group began coverage on Omeros in a research note on Monday, February 1st. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Maxim Group lifted their price target on Omeros from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, December 4th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $22.00.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Recommended Story: Special Purpose Acquisition Company (SPAC)
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.